JP7480048B2 - キナーゼ依存的障害を処置するための化合物 - Google Patents

キナーゼ依存的障害を処置するための化合物 Download PDF

Info

Publication number
JP7480048B2
JP7480048B2 JP2020540745A JP2020540745A JP7480048B2 JP 7480048 B2 JP7480048 B2 JP 7480048B2 JP 2020540745 A JP2020540745 A JP 2020540745A JP 2020540745 A JP2020540745 A JP 2020540745A JP 7480048 B2 JP7480048 B2 JP 7480048B2
Authority
JP
Japan
Prior art keywords
alkyl
alkoxy
compound
cycloalkyl
alkylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020540745A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021511357A5 (cg-RX-API-DMAC10.html
JP2021511357A (ja
Inventor
リン カンヌ バネン,
ミンナ ブイ,
ファミン ジャン,
ヨン ワン,
ウェイ シュー,
Original Assignee
エグゼリクシス, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エグゼリクシス, インコーポレイテッド filed Critical エグゼリクシス, インコーポレイテッド
Publication of JP2021511357A publication Critical patent/JP2021511357A/ja
Publication of JP2021511357A5 publication Critical patent/JP2021511357A5/ja
Application granted granted Critical
Publication of JP7480048B2 publication Critical patent/JP7480048B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2020540745A 2018-01-26 2019-01-25 キナーゼ依存的障害を処置するための化合物 Active JP7480048B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862622702P 2018-01-26 2018-01-26
US201862622626P 2018-01-26 2018-01-26
US62/622,702 2018-01-26
US62/622,626 2018-01-26
PCT/US2019/015296 WO2019148043A1 (en) 2018-01-26 2019-01-25 Compounds for the treatment of kinase-dependent disorders

Publications (3)

Publication Number Publication Date
JP2021511357A JP2021511357A (ja) 2021-05-06
JP2021511357A5 JP2021511357A5 (cg-RX-API-DMAC10.html) 2022-02-24
JP7480048B2 true JP7480048B2 (ja) 2024-05-09

Family

ID=65685938

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020540745A Active JP7480048B2 (ja) 2018-01-26 2019-01-25 キナーゼ依存的障害を処置するための化合物

Country Status (8)

Country Link
US (2) US11673897B2 (cg-RX-API-DMAC10.html)
EP (1) EP3743417A1 (cg-RX-API-DMAC10.html)
JP (1) JP7480048B2 (cg-RX-API-DMAC10.html)
CN (1) CN111936487B (cg-RX-API-DMAC10.html)
AU (1) AU2019212800B2 (cg-RX-API-DMAC10.html)
CA (1) CA3088198A1 (cg-RX-API-DMAC10.html)
MA (1) MA51679A (cg-RX-API-DMAC10.html)
WO (1) WO2019148043A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20251184T1 (hr) * 2018-01-26 2025-12-05 Exelixis, Inc. Spojevi za liječenje poremećaja ovisnih o kinazi
FI4143169T3 (fi) 2020-04-30 2026-06-08 Exelixis Inc Kinaasi-inhibiittorin valmistusmenetelmät
TW202241862A (zh) * 2021-02-01 2022-11-01 大陸商江蘇恆瑞醫藥股份有限公司 二甲醯胺類化合物、其製備方法及其在醫藥上的應用
MX2023009560A (es) * 2021-02-17 2023-10-25 Springworks Therapeutics Inc Solidos cristalinos del inhibidor de mek n-((r)-2,3-dihidroxipropo xi)-3,4-difluoro-2-(2-fluoro-4-yodo-fenilamino)-benzamida y sus usos.
WO2026074526A1 (en) * 2024-10-04 2026-04-09 Hetero Labs Limited 1,2-dicarboxamide compounds as kinase inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007506777A (ja) 2003-09-26 2007-03-22 エグゼリクシス, インコーポレイテッド c−Metモジュレーターおよびその使用
JP2013531016A (ja) 2010-07-14 2013-08-01 ジャージャン ベータ ファーマ インコーポレイテッド c−METチロシンキナーゼ阻害薬として有用な新規な縮合複素環式誘導体
JP2013537197A (ja) 2010-09-12 2013-09-30 アドヴェンチェン ラボラトリーズ,エルエルシー c−Metキナーゼ阻害剤としての化合物

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
ATE446955T1 (de) 1995-03-30 2009-11-15 Pfizer Prod Inc Chinazolinone derivate
GB9508537D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
CN100503580C (zh) 1996-04-12 2009-06-24 沃尼尔·朗伯公司 酪氨酸激酶的不可逆抑制剂
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
KR100600550B1 (ko) 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
WO2005009387A2 (en) 2003-07-23 2005-02-03 X-Ceptor Therapeutics Inc. Azepine derivatives as pharmaceutical agents
WO2006113546A2 (en) 2005-04-15 2006-10-26 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101353763B1 (ko) 2005-11-07 2014-01-21 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 신생 저해 물질과 c―kit 키나아제 저해 물질의병용
US7723330B2 (en) 2006-03-07 2010-05-25 Array Biopharma Inc. Heterobicyclic pyrazole compounds and methods of use
WO2008076415A1 (en) * 2006-12-14 2008-06-26 Exelixis, Inc. Methods of using mek inhibitors
WO2009017838A2 (en) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
AU2009303602B2 (en) * 2008-10-14 2012-06-14 Sunshine Lake Pharma Co., Ltd. Compounds and methods of use
CA2742007C (en) * 2008-10-29 2014-07-08 Deciphera Pharmaceuticals, Llc Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities
EP2214019A1 (en) 2009-01-28 2010-08-04 Externautics S.p.A. Tumor markers and methods of use thereof
EP2213686A1 (en) 2009-01-28 2010-08-04 Externautics S.p.A. Tumor markers and methods of use thereof
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US20130017546A1 (en) 2009-10-26 2013-01-17 Externautics S.P.A. Breast Tumor Markers and Methods of Use Thereof
US10288617B2 (en) 2009-10-26 2019-05-14 Externautics Spa Ovary tumor markers and methods of use thereof
US8921058B2 (en) 2009-10-26 2014-12-30 Externautics Spa Prostate tumor markers and methods of use thereof
WO2011051278A1 (en) 2009-10-26 2011-05-05 Externautics S.P.A. Lung tumor markers and methods of use thereof
WO2011051276A1 (en) 2009-10-26 2011-05-05 Externautics S.P.A. Colon and rectal tumor markers and methods of use thereof
US20120070368A1 (en) 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
EP2383578A1 (en) 2010-04-30 2011-11-02 Externautics S.p.A. Tumor marker and methods of use thereof
CN102093421B (zh) 2011-01-28 2014-07-02 北京康辰药业有限公司 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
CN102408411B (zh) 2011-09-19 2014-10-22 北京康辰药业股份有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
RS61400B1 (sr) 2013-05-02 2021-02-26 Anaptysbio Inc Antitela usmerena protiv programirane smrti-1 (pd-1)
US10359428B2 (en) 2013-06-14 2019-07-23 Externautics S.P.A. Tumor marker, monoclonal antibodies and methods of use thereof
EA201690912A1 (ru) 2013-11-05 2016-10-31 Когнейт Биосервисис, Инк. Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака
JP6696908B2 (ja) * 2014-04-25 2020-05-20 エグゼリクシス, インコーポレイテッド 肺腺癌の治療方法
CN104817497B (zh) 2015-03-20 2017-03-08 南京众睿缘生物科技有限公司 一种炔代喹啉衍生物及其制备方法和用途
CN106279147A (zh) * 2015-05-21 2017-01-04 中国科学院上海药物研究所 一种吡啶并氮杂环化合物及其制备方法和用途
US20180009758A1 (en) 2015-06-29 2018-01-11 Ontogenesis, Llc Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use
US20170342033A1 (en) 2015-06-29 2017-11-30 Ontogenesis, Llc Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use
CN105797123A (zh) 2016-05-18 2016-07-27 王超 一种治疗不孕不育的中药组合物
CN106400155A (zh) 2016-08-31 2017-02-15 飞佛特种纺织品(宁波)有限公司 一种防老化阳光面料
CN110437145A (zh) 2016-09-13 2019-11-12 上海翔锦生物科技有限公司 酪氨酸激酶抑制剂及其应用
US10800741B2 (en) 2017-02-07 2020-10-13 Ancureall Pharmaceutical (Shanghai) Co., Ltd. Quinoline compound, preparation method and medical use therefor
WO2018153293A1 (zh) * 2017-02-27 2018-08-30 北京赛特明强医药科技有限公司 二噁烷并喹唑啉与二噁烷并喹啉类化合物及其制备方法与应用
SG11202005719UA (en) 2017-12-20 2020-07-29 Angex Pharmaceutical Inc Carbamate and urea compounds as multikinase inhibitors
HRP20251184T1 (hr) 2018-01-26 2025-12-05 Exelixis, Inc. Spojevi za liječenje poremećaja ovisnih o kinazi
SG11202006945PA (en) 2018-01-26 2020-08-28 Exelixis Inc Compounds for the treatment of kinase-dependent disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007506777A (ja) 2003-09-26 2007-03-22 エグゼリクシス, インコーポレイテッド c−Metモジュレーターおよびその使用
JP2013531016A (ja) 2010-07-14 2013-08-01 ジャージャン ベータ ファーマ インコーポレイテッド c−METチロシンキナーゼ阻害薬として有用な新規な縮合複素環式誘導体
JP2013537197A (ja) 2010-09-12 2013-09-30 アドヴェンチェン ラボラトリーズ,エルエルシー c−Metキナーゼ阻害剤としての化合物

Also Published As

Publication number Publication date
AU2019212800B2 (en) 2024-05-23
WO2019148043A1 (en) 2019-08-01
AU2019212800A1 (en) 2020-08-20
CA3088198A1 (en) 2019-08-01
EP3743417A1 (en) 2020-12-02
US20210032263A1 (en) 2021-02-04
CN111936487B (zh) 2024-07-09
JP2021511357A (ja) 2021-05-06
MA51679A (fr) 2020-12-02
US11673897B2 (en) 2023-06-13
CN111936487A (zh) 2020-11-13
US20240150371A1 (en) 2024-05-09

Similar Documents

Publication Publication Date Title
JP7690517B2 (ja) キナーゼ依存的障害を処置するための化合物
JP7596427B2 (ja) キナーゼ依存的障害を処置するための化合物
US11673897B2 (en) Compounds for the treatment of kinase-dependent disorders
BR112020015199B1 (pt) Composto, composição farmacêutica e uso dos mesmos para tratar distúrbios dependentes de quinase
HK40046174B (en) Compounds for the treatment of kinase-dependent disorders
HK40043088B (en) Compounds for the treatment of kinase-dependent disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221221

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230320

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230623

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230922

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240312

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240327

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240424

R150 Certificate of patent or registration of utility model

Ref document number: 7480048

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150